Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Braga Neto, Manuel B ^a   Aguiar, Carolina V ^a   Maciel, Jamilly G ^a   Oliveira, Bruna M C ^a   Sevilleja, Jesus E ^b   Oriá, Reinaldo B ^a,b   Brito, Gerly A C ^a   Warren, Cirle A ^b   Guerrant, Richard L ^a,b   Lima, Aldo A M ^a,b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; DIDANOSINE; INDINAVIR; LACTULOSE; MANNITOL; NELFINAVIR; PHOSPHATE BUFFERED SALINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SODIUM; WATER; ZIDOVUDINE; ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; ELECTROLYTE TRANSPORT; FLOW CYTOMETRY; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE CRYPT; INTESTINE EPITHELIUM CELL; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; INTESTINE SECRETION; INTESTINE VILLUS; MALE; MOUSE; NICK END LABELING; NONHUMAN; PERMEABILITY BARRIER; SURVIVAL RATE; TREATMENT DURATION; WASTING SYNDROME; WATER TRANSPORT; WEIGHT REDUCTION; ANIMAL; ANIMAL MODEL; CELL MEMBRANE PERMEABILITY; DRUG EFFECT; ELECTROLYTE BALANCE; INTESTINE MUCOSA; NECROSIS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-RETROVIRAL AGENTS; APOPTOSIS; BODY WEIGHT; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; DIDANOSINE; HIV PROTEASE INHIBITORS; INDINAVIR; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; MICE; MODELS, ANIMAL; NECROSIS; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; SURVIVAL RATE; WATER-ELECTROLYTE BALANCE; ZIDOVUDINE;

EID: 77955354743     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-90     Document Type: Article

References (38)

1. Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F, . HIV 2020 Project The future of antiretroviral therapy: challenges and needs. J Antimicrob Chemother 2010, 65(5):827-35. 10.1093/jac/dkq061, 20228080, HIV 2020 Project.
2. El SY, Vivet-Boudou V, Marquet R. HIV-1 reverse transcriptase inhibitors. Appl Microbiol Biotechnol 2007, 75:723-37. 10.1007/s00253-007-0919-7, 17370068.
3. McKinnon JE, Mellors JW, Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther 2009, 14(1):1-12. 2716749, 19320232.
4. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev 2009, 11(1):30-8.
5. Guarino A, Bruzzese E, De MG, Buccigrossi V. Management of gastrointestinal disorders in children with HIV infection. Paediatr Drugs 2004, 6:347-62. 10.2165/00148581-200406060-00003, 15612836.
6. Tramarin A, Parise N, Campostrini S, Yin DD, Postma MJ, Lyu R, Grisetti R, Capetti A, Cattelan AM, Di Toro MT, Mastroianni A, Pignattari E, Mondardini V, Calleri G, Raise E, Starace F, . Palladio Study Group Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res 2004, 13:243-50. 10.1023/B:QURE.0000015282.24774.36, 15058804, Palladio Study Group.
7. Bode H, Lenzner L, Kraemer OH, Kroesen AJ, Bendfeldt K, Schulzke JD, Fromm M, Stoltenburg-Didinger G, Zeitz M, Ullrich R. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells. Antivir Ther 2005, 10:645-55.
8. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future?. Lancet Oncol 2009, 10(1):61-71. 10.1016/S1470-2045(08)70334-6, 19111246.
9. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007, 13(17):5183-94. 10.1158/1078-0432.CCR-07-0161, 17785575.
10. Rufo PA, Lin PW, Andrade A, Jiang L, Rameh L, Flexner C, Alper SL, Lencer WI. Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. Am J Physiol Cell Physiol 2004, 286:C998-C1008. 10.1152/ajpcell.00357.2003, 15075198.
11. Wuhib T, Silva TM, Newman RD, Garcia LS, Pereira ML, Chaves CS, Wahlquist SP, Bryan RT, Guerrant RL, Sousa A de Q, Queiroz TRB, Sears CL. Cryptosporidial and microsporidial infections in human immunodeficiency virus-infected patients in northeastern Brazil. J Infect Dis 1994, 170:494-97.
12. Bushen OY, Davenport JA, Lima AB, Piscitelli SC, Uzgiris AJ, Silva TM, Leite R, Kosek M, Dillingham RA, Girao A, Lima AA, Guerrant RL. Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil. Clin Infect Dis 2004, 38:1764-70. 10.1086/421394, 15227625.
13. Berkes J, Viswanathan VK, Savkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003, 52:439-51. 10.1136/gut.52.3.439, 1773546, 12584232.
14. Bjerknes M, Cheng H. Clonal analysis of mouse intestinal epithelial progenitors. Gastroenterology 1999, 116:7-14. 10.1016/S0016-5085(99)70222-2, 9869596.
15. Potten CS. Stem cells in gastrointestinal epithelium: numbers, characteristics and death. Philos Trans R Soc Lond B Biol Sci 1998, 353:821-30. 10.1098/rstb.1998.0246, 1692280, 9684279.
16. Clatworthy JP, Subramanian V. Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: emerging insights from gene expression patterns, transgenic and gene ablation studies. Mech Dev 2001, 101:3-9. 10.1016/S0925-4773(00)00557-8, 11231054.
17. Fuchs BC, Bode BP. Stressing Out Over Survival: Glutamine as an Apoptotic Modulator. J Surg Res 2006, 131(1):26-40. 10.1016/j.jss.2005.07.013, 16154153.
18. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G, . Nomenclature Committee on Cell Death 2009 Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009, 16(1):3-11. 10.1038/cdd.2008.150, 2744427, 18846107, Nomenclature Committee on Cell Death 2009.
19. Bao Y, Silva TM, Guerrant RL, Lima AM, Fox JW. Direct analysis of mannitol, lactulose and glucose in urine samples by high-performance anion-exchange chromatography with pulse amperometric detection. Clinical evaluation of intestinal permeability in human immunodeficiency virus infection. J Chromatogr B Biomed Appl 1996, 685:105-12. 10.1016/0378-4347(96)00159-4, 8930758.
20. Schedl HP, Clifton JA. Solute and water absorption by the human small intestine. Nature 1963, 199:1264-7. 10.1038/1991264a0, 14074590.
21. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000, 59:581-620. 10.2165/00003495-200059030-00014, 10776836.
22. Lemberg DA, Palasanthiran P, Goode M, Ziegler JB. Tolerabilities of antiretrovirals in paediatric HIV infection. Drug Saf 2002, 25:973-91. 10.2165/00002018-200225140-00001, 12408730.
23. Jarvis B, Nelfinavir Faulds D. A review of its therapeutic efficacy in HIV infection. Drugs 1998, 56:147-67. 10.2165/00003495-199856010-00013, 9664204.
24. Guttman JA, Li Y, Wickham ME, Deng W, Vogl AW, Finlay BB. Attaching and effacing pathogen-induced tight junction disruption in vivo. Cell Microbiol 2006, 8:634-45. 10.1111/j.1462-5822.2005.00656.x, 16548889.
25. Utech M, Bruwer M, Nusrat A. Tight junctions and cell-cell interactions. Methods Mol Biol 2006, 341:185-95.
26. Laukoetter MG, Bruewer M, Nusrat A. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol 2006, 22:85-9. 10.1097/01.mog.0000203864.48255.4f, 16462161.
27. Gasbarrini G, Montalto M. Structure and function of tight junctions. Role in intestinal barrier. Ital J Gastroenterol Hepatol 1999, 31:481-8.
28. Ullrich R, Zeitz M, Heise W, L'age M, Hoffken G, Riecken EO. Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann Intern Med 1989, 111:15-21.
29. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004, 200:761-70. 10.1084/jem.20041196, 2211967, 15365095.
30. Barboza Junior MS, Silva TM, Guerrant RL, Lima AA. Measurement of intestinal permeability using mannitol and lactulose in children with diarrheal diseases. Braz J Med Biol Res 1999, 32:1499-504.
31. Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. New Microbiol 2007, 30:79-88.
32. Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD, Spitz FR. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 2007, 1; 67(3):1221-7.
33. Wu X, Sun L, Zha W, Studer E, Gurley E, Chen L, Wang X, Hylemon PB, Pandak WM, Sanyal AJ, Zhang L, Wang G, Chen J, Wang JY, Zhou H. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 2010, 138(1):197-209. 10.1053/j.gastro.2009.08.054, 19732776.
34. McGowan I, Elliott J, Fuerst M, Taing P, Boscardin J, Poles M, Anton P. Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J Acquir Immune Defic Syndr 2004, 37:1228-36. 10.1097/01.qai.0000131846.12453.29, 15385729.
35. Ullrich R, Zeitz M, Riecken EO. Enteric immunologic abnormalities in human immunodeficiency virus infection. Semin Liver Dis 1992, 12:167-74. 10.1055/s-2007-1007388, 1636119.
36. Nannini EC, Okhuysen PC. HIV1 and the gut in the era of highly active antiretroviral therapy. Curr Gastroenterol Rep 2002, 4:392-8. 10.1007/s11894-002-0009-z, 12228041.
37. Lima AA, Silva TM, Gifoni AM, Barrett LJ, McAuliffe IT, Bao Y, Fox JW, Fedorko DP, Guerrant RL. Mucosal injury and disruption of intestinal barrier function in HIV-infected individuals with and without diarrhea and cryptosporidiosis in northeast Brazil. Am J Gastroenterol 1997, 92:1861-6.
38. Carneiro-Filho BA, Bushen OY, Brito GA, Lima AA, Guerrant RL. Glutamine analogues as adjunctive therapy for infectious diarrhea. Curr Infect Dis Rep 2003, 5:114-9. 10.1007/s11908-003-0046-2, 12641996.